Gene · 51547
Papers2,721
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,721
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Interplay Between the Circadian Clock and Sirtuins. | Int J Mol Sci | 2024 | 39519022 | PubTator, text mining | PubMed |
| Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. | Theranostics | 2024 | 39479446 | PubTator, text mining | PubMed |
| A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5. | Nat Immunol | 2024 | 39424985 | PubTator, text mining | PubMed |
| SIRT7 inhibits the aging and inflammatory damage of hPDLFs by suppressing the AKT/mTOR. | Int Immunopharmacol | 2024 | 39378651 | PubTator, text mining | PubMed |
| Post-Translational Modifications of RNA-Modifying Proteins in Cellular Dynamics and Disease Progression. | Adv Sci (Weinh) | 2024 | 39377984 | PubTator, text mining | PubMed |
| Exosomal non-coding RNAs: Emerging insights into therapeutic potential and mechanisms in bone healing. | J Tissue Eng | 2024 | 39371940 | PubTator, text mining | PubMed |
| Comprehensive succinylome analyses reveal that hyperthermia upregulates lysine succinylation of annexin A2 by downregulating sirtuin7 in human keratinocytes. | J Transl Int Med | 2024 | 39360157 | PubTator, text mining | PubMed |
| Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis. | Anticancer Res | 2024 | 39348999 | PubTator, text mining | PubMed |
| SIRT7 protects against liver fibrosis by suppressing stellate cell activation via TGF-β/SMAD2/3 pathway. | Biomed Pharmacother | 2024 | 39316972 | PubTator, text mining | PubMed |
| SIRT7 remodels the cytoskeleton via RAC1 to enhance host resistance to Mycobacterium tuberculosis. | mBio | 2024 | 39287444 | PubTator, text mining | PubMed |
| Unraveling the multifaceted role of SIRT7 and its therapeutic potential in human diseases. | Int J Biol Macromol | 2024 | 39218192 | PubTator, text mining | PubMed |
| Stratifying osteosarcoma patients using an epigenetic modification-related prognostic signature: implications for immunotherapy and chemotherapy selection. | Transl Cancer Res | 2024 | 39145082 | PubTator, text mining | PubMed |
| Mechanism of desuccinylation of G6PD mediated by SIRT7 to promote vitiligo disease progression. | Immun Inflamm Dis | 2024 | 39092715 | PubTator, text mining | PubMed |
| Sirt7 protects against vascular calcification via modulation of reactive oxygen species and senescence of vascular smooth muscle cells. | Free Radic Biol Med | 2024 | 39053861 | PubTator, text mining | PubMed |
| Monitoring nucleolar-nucleoplasmic protein shuttling in living cells by high-content microscopy and automated image analysis. | Nucleic Acids Res | 2024 | 39036969 | PubTator, text mining | PubMed |
| The SIRT7-nucleolus connection in cancer: ARF enters the fray. | Mol Cell Oncol | 2024 | 39036727 | PubTator, text mining | PubMed |
| LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation. | BMC Cancer | 2024 | 39020302 | PubTator, text mining | PubMed |
| Sirtuin insights: bridging the gap between cellular processes and therapeutic applications. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | 38976046 | PubTator, text mining | PubMed |
| SIRT7 Inhibits Melanin Synthesis of PIG1 and PIG3V by Suppressing the Succinylation of EZR. | Clin Cosmet Investig Dermatol | 2024 | 38933605 | PubTator, text mining | PubMed |
| The Expression of a Subset of Aging and Antiaging Markers Following the Chondrogenic and Osteogenic Differentiation of Mesenchymal Stem Cells of Placental Origin. | Cells | 2024 | 38920652 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51547/papers?page=9